Current state of thrombolytic therapy

Current Cardiology Reports

Volumn 1, Issue 3, 1999, Pages 212-220

  Vorchheimer, David A ^a  

^a MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOLYTIC AGENT; LANOTEPLASE; PLASMINOGEN ACTIVATOR; RECOMBINANT PROTEIN; RETEPLASE; SARUPLASE; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; FIBRINOLYTIC THERAPY; HEART INFARCTION; HEART MUSCLE REPERFUSION; HUMAN; METHODOLOGY; RANDOMIZED CONTROLLED TRIAL; REVIEW; SURVIVAL;

FIBRINOLYTIC AGENTS; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; PLASMINOGEN ACTIVATORS; RANDOMIZED CONTROLLED TRIALS; RECOMBINANT PROTEINS; STREPTOKINASE; SURVIVAL ANALYSIS; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; URINARY PLASMINOGEN ACTIVATOR;

EID: 0033187271     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-999-0025-9     Document Type: Article

References (53)

1. Herrick JB: Clinical features of sudden obstruction of the coronary arteries. JAMA 1912, 59:2015-2020.
2. DeWood MA, Spores J, Notskes, et al.: Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980, 303:897-902.
3. Reimer KA, Jennings RB: The wavefront phenomenon of myocardial ischemic cell death. II. Transmural progression of necrosis within the framework of ischemic bed size (myocardium at risk) and collateral flow. Lab Invest 1979, 40:633-644.
4. Lijnen RH, Collen D, Verstraete M: Thrombolytic agents. In Cardiovascular Thrombosis: Thrombocardiology and Thromboneurology 2nd edn. Edited by Verstraete M, Fuster V, Topol EJ. Philadelphia: Lippincott-Raven Publishers; 1998:301-320.
5. Collen D, Bounameaux H, De Cook F, et al.: Analysis of coagulation and fibrinolysis during intravenous infusion of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarction. Circulation 1986, 73:511-517.
6. Ryan TJ, Anderson JL, Antman EM, et al.: ACC/AHA guidelines for the management of patients with acute myocardial infarction: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol 1996, 28:1328-1428.
7. Barron HV, Bowlby LJ, Brren T, et al.: Use of reperfusion therapy for acute myocardial infarction in the United States: data from the National Registry of Myocardial Infarction 2. Circulation 1998, 97:1150-1156.
8. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group: ISIS-4: a randomized factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995, 345:669-685.
9. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group: Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994, 343:311-322.
10. Boersma E, Maas ECP, Deckers JW: Early thrombolytic treatment in acute myocardial infraction: reappraisal of the golden hour. Lancet 1996, 348:771-775.
11. Newby LK, Rutsch WR, Califf RM, et al.: Time from symptom onset to treatment and outcomes after thrombolytic therapy. J Am Coll Cardiol 1996, 27:1646-1655.
12. Topol EJ, Van de Werf, FJ: Acute myocardial infarction: early diagnosis and management. In Textbook of Cardiovascular Medicine. Edited by Topol, EJ. Philadelphia: Lippincott-Raven Publishers; 1998:395-435.
13. Mak KH, Moliterno DJ, Granger CB, et al.: Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. J Am Coll Cardiol 1997, 30(1):171-179.
14. Mahaffey KW, Granger CB, Toth CA, et al.: Diabetic retinopathy should not be a contraindication to thrombolytic therapy for acute myocardial infarction: review of ocular hemorrhage incidence and location in the GUSTO-I trial. J Am Coll Cardiol 1997, 30:1606-1610.
15. Karnaash SL, Granger CB, White HD, et al.: Treating menstruating women with thrombolytic therapy: insights from the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO-I) Trial. J Am Coll Cardiol 1995, 26:1651-1656.
16. Vorchheimer DA, Baruch L, Kukin ML, et al.: Does the presence or absence of chest pain at initiation of thrombolysis in acute myocardial infarction affect outcome [abstract]? J Am Coll Cardiol 1996, 27:389A.
17. White HD, Van de Werf FJJ. Thrombolysis for acute myocardial infarction. Circulation 1998, 97:1632-1646.
18. Granger CB, White H, Simoons M, et al.: Risk factors for stroke following thrombolytic therapy: case controlled study from the GUSTO trial [abstract]. J Am Coll Cardiol 1995, 25:232A.
19. DeFranco AC, Abramouritz B, Kirchbaum D, et al.: Substantial (threefold) benefit of accelerated t-PA over standard thrombolytic therapy in patients with prior coronary bypass surgery and acute MI: results of the GUSTO trial [abstract]. J Am Coll Cardiol 1994, 23:345A.
20. The International Study Group: In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. Lancet 1990, 336:71-75.
21. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group: A randomized comparison of streptokinase versus tissue plasminogen activator versus anistreplase and of aspirin plus heparin versus aspirin alone in 41,299 cases of suspected acute myocardial infarction: ISIS-3 Lancet 1992, 339:753-770.
22. The GUSTO Investigators: An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993, 329:673-682.
23. Mark DB, Hlatky MA, Califf RM, et al.: Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med 1995, 332:1418-1424.
24. The GUSTO Angiographic Investigators: The effects of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993, 329:1615-1622.
25. Ito H, Maruyama A, Iwakura K, et al.: Clinical implications of the "no reflow" phenomenon: a predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction. Circulation 1996, 93:223-228.
26. Wu K, Zerhouni EA, Judd RM, et al.: Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction. Circulation 1998, 97:765-772.
27. Topol EJ: Toward a new frontier in myocardial reperfusion therapy: emerging platelet preeminence. Circulation 1998, 97:211-218.
28. Brener SJ, Topol EJ: Third-generation thrombolytic agents for acute myocardial infarction. In Acute Coronary Syndromes, edited by Topol, EJ. New York: Marcel Dekker; 1998:167-192.
29. The COBALT Investigators: A comparison of continuous infusion of alteplase with double-bolus administration for acute myocardial infarction. N Engl J Med 1997, 337:1124-1130.
30. Bleich SD, Adgey AAJ, McMechan SR, Love TJ, for the DouBLE Study Investigators: An angiographic assessment of alteplase: double-bolus and front-loaded infusion regimens in myocardial infarction. Am Heart J 1998, 136:741-748.
31. Antman EM, Braunwald E: Acute myocardial infarction. In Heart Disease: A Textbook of Cardiovascular Medicine, 5th edn. Edited by Braunwald, E. Philadelphia: WB Saunders Company; 1997:1184-1289.
32. The Global Use of Strategies to Open Occluded Arteries (GUSTO-III) Investigators: A comparison of retaplase with alteplase for acute myocardial infarction. N Engl J Med 1997, 337:1118-1123.
33. Smalling RW, Bode C, Kalbfleisch J, et al.: for the RAPID Investigators: More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. Circulation 1995, 91:2725-2732.
34. Bode C, Smalling RW, Berg G, et al.: Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. Circulation 1996, 94:891-898.
35. International Joint Efficacy Comparison of Thrombolytics: Randomised, double-blind comparison of reteplase double bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence. Lancet 1995, 346:329-336
36. Gurbel PA, Serebruany VL, Shustov AR, et al.: Effects of retaplase and alteplase on platelet aggregation and major receptor expression during the first 24 hours of acute myocardial infarction. J Am Coll Cardiol 1998, 31:1466-1473.
37. Ross AM: New plasminogen activators: a clinical review. Clinical Cardiology 1999, 22:165-171.
38. Collen D, Stassen JM, Yasuda T, et al.: Comparative thrombolytic properties of tissue-type plasminogen activator and of a plasminogen activator inhibitor-1-resistant glycosylation variant, in a combined arterial and venous thrombosis model in the dog. Thromb Haemost 1994, 72:98-104.
39. Demarco E, Rebuzzi AG, Quaranta G, et al.: Lack of procoagulant effect after TNK-plasminogen activator in patients with acute myocardial infarction. Eur Heart J 1998, 19(suppl):5.
40. Cannon CP, McCabe CH, Gibson M, et al.: TNK-tissue plasminogen activator in acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trial. Circulation 1997, 95:351-356.
41. Cannon CP, Gibson M, McCabe CH, et al.: TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Circulation 1998, 98:2805-2814.
42. Van de Werf F, Cannon C P, Luyten A, et al.: Safety assessment of single-bolus administration of TNK-tissue plasminogen activator in acute myocardial infarction: the ASSENT-1 trial. Am Heart J 1999, 137:786-791.
43. den Heijer P, Vermeer F, Ambrosioni E, et al.: for the InTIME Investigators. Evaluation of a weight-adjusted single-bolus plasminogen activator in patients with myocardial infarction: a double-blind, randomized angiographic trial of lanoteplase versus alteplase. Circulation 1999, 98:2117-2125.
44. Kawai C, Yoshiki Y, Hosada S, et al.: A prospective, randomized, double-blind multicenter trial of a single bolus injection of the novel modified t-PA E6010 in the treatment of acute myocardial infarction: comparison with native t-PA. J Am Coll Cardiol 1997, 27:1447-1453.
45. PRIMI Trial Study Group: Randomized, double-blind trial of recombinant pro-urokinase against streptokinase in acute myocardial infarction. Lancet 1989, 1:863-868.
46. Tebbe U, Michels R, Adgey J, et al.:for the COMPASS Investigators: Randomized, double-blind study comparing saruplase with streptokinase therapy in acute myocardial infarction: the COMPASS equivalence trial. J Am Coll Cardiol 1998, 31:487-493.
47. Bar F, Hopkins G, Dickhoet S, et al.: The bolus versus infusion rescuepase (saruplase) development (BIRD) study in 2,416 patients with acute myocardial infarction [abstract]. Circulation 1998, 98(suppl):I-505.
48. Jespers L, Vanwetswinkel S, Lijnen HR, et al.: Structural and functional basis of plasminogen activation by staphylokinase. Thromb Haemost 1999, 81: 479-485.
49. Vanderschueren S, Dens J, Kerdsinchai P, et al.: Randomized coronary patency trial of recombinant staphylokinase versus front-loaded alteplase in acute myocardial infarction. Am Heart J 1997, 134:213-219.
50. Vanderschueren S, Barrios L, Kerdsinchai P, et al.: for the STAR Trial Group. A randomized trial of recombinant staphylokinase versus alteplase for coronary artery patency in acute myocardial infarction. Circulation 1995, 92:2044-2049.
51. Antman M, Giugliano RP, Gibson CM, et al.: Abciximab facilitates the rate and extent of thrombolysis: results of the Thrombolysis in Myocardial Infarction (TIMI) 14 Trial. Circulation 1999, 99:2720-2732.
52. Vorchheimer DA, Badimon JJB, Fuster V: Platelet glycoprotein IIb/IIIa receptor antagonists in cardiovascular disease. JAMA 1999, 281:1407-1414.
53. Vorchheimer DA, Muller DWM: Adjunctive antithrombotic treatment to thrombolysis in acute myocardial infarction. In Cardiovascular Thrombosis: Thrombocardiology and Thromboneurology edn 2. Edited by Verstraete M, Fuster V, Topol EJ. Philadelphia: Lippincott-Raven Publishers;1998:511-575.